The new heparins

Coronary Artery Disease

Volumn 9, Issue 2-3, 1998, Pages 65-74

  Bates, Shannon M ^a   Weitz, Jeffrey I ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Heparin; Heparinoids; Low molecular weight heparin; Pentasaccharide

Indexed keywords

ANTICOAGULANT AGENT; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE;

CORONARY ARTERY OBSTRUCTION; HEART MUSCLE ISCHEMIA; PRIORITY JOURNAL; RESTENOSIS; REVIEW; UNSTABLE ANGINA PECTORIS;

EID: 0031862825     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199802000-00002     Document Type: Review

References (121)

1. Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured endothelial cells. Thromb Res 1978, 12:73-82.
2. Hiebert LM, Jacques LB. The observation of heparin on the endothelium after injection. Thromb Res 1976, 8:195-204.
3. Lane DA. Heparin binding and neutralizing proteins. In Lane DA, Lindahl U, editors. Heparin: chemical and biological properties and clinical applications. Boca Raton, FL: CRC Press, Inc.; 1989. pp. 363-391.
4. Sobel M, McNeil PM, Carlson PL, Kermode JC, Adelman B, Conroy R, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991, 87:1787-1793.
5. deRomeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu-evidence of the importance of the multimerization degree of vWF. Thromb Haemost 1993, 69:436-440.
6. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992, 67:639-643.
7. Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976, 53:691-695.
8. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327:141-145.
9. Oldgren J, Grip L, Wallentin L. Reactivation after cessation of thrombin inhibition in unstable coronary artery disease, regardless of aspirin dose. Circulation 1996, 94 (suppl 1):I-431 [abstract 2515].
10. Popma JJ, Coller BS, Ohman EM, Bittle JA, Weitz J, Kuntz RE, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1995, 108 (suppl):486S-501S.
11. Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett DL, et al. Warfarin sodium vs. low dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979, 301:855-858.
12. Coon WW, Willis PW III, Symons MJ. Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg 1969, 170:596-597.
13. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson W. Need for long-term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 1985, 2:515-518.
14. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
15. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989, 86:3619-3623.
16. Levine MN, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost 1986, 12:39-57.
17. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984, 100:535-540.
18. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, et al. Heparin effect on bone density. Thromb Haemost 1990, 64:286-289.
19. Curry N, Bandana EJ, Pirofsky B. Heparin sensitivity: report of a case. Arch Intern Med 1973, 132:744-745.
20. Jacques LB. Heparins-anionic polyelectrolyte drugs. Pharmacol Rev 1980, 31:99-166.
21. White RW, Sadd JR, Nensel RE. Thrombotic complications of heparin therapy, including six cases of heparin-induced skin necrosis. Ann Surg 1979, 190:595-608.
22. O'Kelly R, Magee F, McKenna J. Routine heparin therapy inhibits adrenal aldosterone production. J Clin Endocrinol Metab 1983, 56:108-112.
23. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996, 334:682-687.
24. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996, 334:677-681.
25. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997, 337:657-662.
26. Simonneau G, Sors H, Charbonnier B, Page Y, Labaan J-P, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997, 337:663-669.
27. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997, 96:61-68.
28. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447-452.
29. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
30. Ofosu FA, Barrowcliffe TW. Mechanisms of action of low-molecular weight heparins and heparinoids. Bailliere's Clin Haematol 1990, 3:505-529.
31. Hirsh J, Levine MN. Low-molecular-weight heparin: laboratory properties and clinical evaluation. A review. Eur J Surg 1994, 571 (suppl):9-22.
32. Rosenberg RD, Bauer KA. The heparin-antithrombin system. A natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia, PA: Lippincott; 1994. pp. 837-860.
33. Harenberg J. Pharmacology of low-molecular-weight heparins. Semin Thromb Haemost 1998, 16 (suppl):12-18.
34. Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986, 261:15467-15473.
35. Jordon RE, Oostra GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980, 255:100081-100090.
36. Sandset PM, Abilgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988, 50:803-813.
37. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995, 74:90-93.
38. Huang ZF, Wun T-C, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993, 268:26950-260505.
39. Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochem Biophys Acta 1985, 845:196-203.
40. Young E, Wells, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low-molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994, 71:300-304.
41. Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low-molecular-weight heparin (enoxaparin) to plasma proteins. Thromb Haemost 1993, 70: 625-630.
42. Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985, 30:631-636.
43. Handeland GF, Abilgaard U, Holm HA, Arnesen K-E. Dose-adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low-molecular-weight heparin. Eur J Clin Pharmacol 1990, 30:107-112.
44. Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, et al. Pharmacokinetic studies of standard unfractionated heparin and low-molecular-weight heparins in the rabbit. Semin Thromb Hemost 1988, 14:18-27.
45. Weitz J. Low-molecular-weight heparins. N Engl J Med 1997, 337:688-698.
46. Cadroy Y, Pourrat J, Baladre MF, Savin S, Houin G, Montastruc L, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991, 63:385-390.
47. Amiral J, Bridey F, Wolf M, Boyer-Neumann E, Fressinaud E, Vissac AM, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995, 73:21-28.
48. Monreal M, Lafoz E, Olive A, del Rio L, Vedi C. Comparison of subcutaneous unfractionated heparin with a low-molecular-weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994, 71:7-11.
49. Carter CJ, Kelton JG, Hirsh J, Cerskus AL, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low-molecular-weight heparin in rabbits. Blood 1982, 59:1239-1245.
50. Horne MK III, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990, 74:306-312.
51. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980, 65:64-73.
52. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low-molecular-weight heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci 1989, 556:245-254.
53. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, et al. Low-molecular-weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995, 26:313-318.
54. Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996, 347:561-568.
55. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: results of TIMI 11a. J Am Coll Cardiol 1997, 29:1474-1482.
56. Hanke H, Oberhoff M, Hanke S, Hassenstein S, Kamenz J, Schmid KM, et al. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin. Circulation 1992, 85:1548-1556.
57. Buchwald AB, Unterberg C, Hebendahl K, Crone HJ, Wiegard V. Low-molecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs. Circulation 1992, 86:531-536.
58. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, et al. Low molecular weight heparin in prevention of restenosis after angioplasty: results of enoxaparin restenosis (ERA) trial. Circulation 1994, 90:908-914.
59. Cairns JA, Gill J, Morton B, Roberts R, Gent M, Hirsh J, et al. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: the EMPAR study. Circulation 1996, 94:1553-1560.
60. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 1988, 18 (suppl 3): 3-15.
61. Bara L, Samama MM. Pharmacokinetics of low-molecular-weight heparins. Acta Chir Scand Suppl 1988, 543:65-72.
62. Boneu B. An international multicentre study: clivarin in the prevention of venous thromboembolism in patients undergoing general surgery: report of the International Clivarin Assessment Group. Blood Coagul Fibrinolysis 1993, 4 (suppl 1):S1-S22.
63. Dutton DA, Hotersall AP, MeLaren AD, Taylor KM, Turner MA. Protamine titration after cardiopulmonary bypass. Anaesthesia 1983, 38:264-268.
64. Woltzt M, Weltermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, et al. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 1995, 73:439-443.
65. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost 1990, 63:271-274.
66. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CNL. Heparin-induced thrombocytopenia: studies with a new low-molecular-weight heparinoid, Org 10172. Blood 1989, 73:1592-1596.
67. Leroy J, Leclerc MN, Delahousse B, Guerois S, Goloppe P, Gruel Y, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low-molecular-weight heparin (CY216). Semin Thromb Haemost 1985, 11:326-329.
68. Vitoux JF, Mathier JF, Roncato M, Fiessinger JH, Aiach M. Heparin-associated thrombocytopenia treatment with low-molecular-weight heparin. Thromb Haemost 1986, 55:37-39.
69. Horellou MH, Conrad J, Lecrubier C, Samama M, Roque-d'Orbacastel A, de Fenoly O, et al. Persistent heparin-induced thrombocytopenia despite therapy with low-molecular-weight heparin (letter). Thromb Haemost 1984, 51:134.
70. Magnani HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993, 70:554-561.
71. Forestier F, Daffos F, Capella-Pavolovsky M. Low-molecular-weight heparin (FK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res 1984, 34:357-360.
72. Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, et al. Use of low-molecular-weight heparin in pregnancy. Thromb Haemost 1992, 68:652-656.
73. Meuleman DG. Orgaran (ORG 10172): its pharmacological profile in experimental models. Haemostasis 1992, 22:55-65.
74. Meuleman DG, Hobbelen PMJ, van Dedem G, Moelker HC. A novel anti-thrombotic heparinoid (ORG 10172) devoid of bleeding-inducing capacity in experimental animal models. Thromb Res 1982, 27:353-363.
75. van Dinther TG, Hol F, Meuleman DG. Effect of various heparin(oid)s on heparin cofactor II mediated anti-thrombin activity and inhibition of thrombin generation in vitro. Thromb Haemost 1987, 58:423.
76. Danhof M, de Boer A, Magnani MN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (ORG 10172) therapy. Haemostasis 1992, 22:73-84.
77. Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, et al. Double-blind randomized trial of ORG 10172 low molecular weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke. Lancet, 1987, 1:523-526.
78. Turpie AGG, Levine MN, Powers P, Ginsberg JS, Jay R, Klimek M, et al. Double-blind randomized trial of ORG 10172 low molecular weight heparinoid vs. unfractionated heparin in the prevention of deep vein thrombosis in patients with thrombotic stroke [abstract]. Thromb Haemost 1991, 65:753.
79. Duman R, Wointinas F, Kutnowski M, Nikolic I, Bernenon R, Abedinpour F, et al. A multicentre double-blind randomized study to compare the safety and efficacy of once daily ORG 10172 and twice daily low-dose heparin in preventing deep vein thrombosis in patients with ischemic stroke. Age Ageing 1994, 23:512-516.
80. Bergqvist D, Kettunen K, Fredin H, Fauno P, Soulomalainen O, Suimakallio S, et al. Thromboprophylaxis in patients with hip fracture: a prospective randomized comparative study between ORG 10172 and Dextran 70. Surgery 1991, 109:617-622.
81. Gerhart T, Yett HS, Robertson L, Lee MA, Smith M, Salzman E. Low molecular weight heparinoid compared with warfarin for prophylaxis of deep vein thrombosis in patients operated on for fractures of the hip. J Bone Joint Surg 1991, 73A: 494-502.
82. Hoek JA, Nurmohamed MT, Hamelynck KJ, Marti RK Knipscheer HC, ten Cate H, et al. Prevention of deep vein thrombosis following total hip replacement by low-molecular weight heparinoid. Thromb Haemost 1992, 67:28-32.
83. Leyvraz P, Bachmann F, Bonnet J, Breyer HG, Estoppey D, Haas S, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid lomoparan and heparin-dihydroergotamine. Br J Surg 1992, 79:911-914.
84. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, et al. Low-molecular-weight heparinoid Orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996, 93:80-84.
85. de Walk HW, Banga JD, Wester JWJ, Brouwer CB, van Hessen MWJ, Meuwissen OJA, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism - a randomized controlled trial. Ann Intern Med 1995, 123:1-9.
86. Doherty D, Ortel T, Debruijn N, Greenberg D, Van Trigt P. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (ORG 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990, 73:562-565.
87. Rowlings PA, Mansberg R, Rozenberg MC, Evans S, Murray BL. The use of a low molecular weight heparinoid (ORG 10172) for extracorporeal procedures in patients with heparin-dependent thrombocytopenia and thrombosis. Aust N Z J Med 1991, 21:52-54.
88. Stiekma JCJ, Wignana HP, ten Cate H, ten Cate JW, Harenberg J, Egberts JCM, et al. Partial in vivo neutralization of plasma anticoagulant effects of Lomoparan (ORG 10172) by protamine chloride. Thromb Res 1991, 63:157-167.
89. Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, et al. A comparison of the antithrombotic and haemorrhagic effects of low-molecular-weight heparin fractions: the influence of the method of preparation. Thromb Res 1984, 35:613-625.
90. Hobbelen PMJ, Vogel GMJ, Meuleman DG. Time courses of the antithrombotic effects, bleeding enhancing effect and interaction with factor Xa and thrombin after administration of low molecular weight heparinoid ORG 10172 or heparin to rats. Thromb Res 1987, 48:549-558.
91. ten Cate H, Henny CP, Mooy MC, ten Cate JW, Surachno S, Wilmink JM. The anticoagulant and antithrombotic effects of heparinoid in haemodialysis patients and human volunteers [abstract]. Thromb Haemostas 1983, 50:302.
92. Mikhailidis DP, Barradas MA, Mikhailidis AM, Magnani H, Dandona P. Comparison of the effect of a conventional heparin and low-molecular-weight heparinoid on platelet function. Br J Clin Pharmacol 1984, 17:43-48.
93. Fareed J, Hoppensteadt D, Walenga JM, Ahsan A, Coyne E, Breddin HK. Molecular and functional heterogeneity in dermatan sulfate preparations. Semin Thromb Haemost 1991, 17:174-180.
94. Tollefson DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983, 258:6713-6717.
95. Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effect of heparin. Blood 1985, 65:198-201.
96. Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986, 64:309-317.
97. Menton RE, Thomas DP. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Thromb Haemost 1987, 58:839-842.
98. Van Ryn-McKenna J, Ofosu F, Hirsh J, Buchanan M. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulphation. Br J Haematol 1989, 71:265-269.
99. Van Ryn-McKenna J, Gray E, Weber E, Ofosu FA, Buchanan MR. Effect of sulphated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 1989, 61:6-9.
100. Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh J, Buchanan MR. Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann N Y Acad Sci 1989, 556:304-312.
101. Bendayan P, Coccalon H, Dupouy D, Boneu B. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemostas 1994, 71:576-580.
102. Boneu B, Buchanan MR, Cade JF, Van Ryn J, Fernandez FF, Ofosu FA, et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985, 40:81-89.
103. Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. J Lab Clin Med 1991, 117:359-364.
104. Messmore J-HL, Griffin B, Fareeh J, Coyne E, Seghatchian J. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann N Y Acad Sci 1989, 556:217-232.
105. Dol F, Houin G, Rostin M, Montastruc JL, Dupouy D, Ginase F, et al. Pharmacokinetics and phamacodynamics of dermatan sulfate in humans. Blood 1989, 74:1577-1582.
106. Dol F, Petitou M, Lormeau J, Choay J, Caranobe C, Sie P, et al. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulphate. J Lab Clin Med 1989, 115:43-51.
107. Dettori AG, Gaiil G, Manotti C, Palazzini E. Pharmacological activity of a low molecular weight dermatan sulfate (desmin) in healthy volunteers. Semin Thromb Haemost 1994, 20:259-265.
108. Sinay P, Jacquinet J, Petitou M, Duchaussoy P, Lederman I, Choay J, et al. Total synthesis of a heparin pentasaccharide fragment having high affinity for AT III. Carbohydr Res 1984, 132:C5-C9.
109. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologie rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997, 86:1-36.
110. Herbert JM, Herault JP, Bernat A, van Amsterdam GMT, Vogel JC, Petitou M, et al. Biochemical and pharmacologie properties of SANORG 32701: comparison with the "synthetic pentasaccharide" (SR 90107/ORG31540) and standard heparin. Circ Res 1996, 79:590-600.
111. Zitoun D, Bara L, Bloch MF, Samama MM. Plasma TFPI activity after intravenous injection of pentasaccharide (PS) and unfractionated heparin in rabbits. Thromb Res 1994, 75:577-580.
112. Lojewski B, Bacher P, Jeske W, Fareed J. Molecular weight dependence on the release of tissue factor pathway inhibitor after subcutaneous and intravenous actions of heparins [abstract]. Thromb Haemost 1993, 69:1174.
113. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 3140 on thrombin generation ex vivo is uniquely due to AT-mediated neutralization of factor Xa. Thromb Haemost 1995, 74:1474-1477.
114. Hobbellen PMJ, Van Dinther TJ, Vogel GM, Van Boeckel CAA, Moelker HCT, Meulman DG. Pharmacologie profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990, 63:265-270.
115. Amar J, Caranobe P, Sie P, Boneu B. Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities. An experimental study in two models of thrombosis in the rabbit. Br J Haematol 1990, 76:94-100.
116. Thomas DP, Merton RE, Gray E, Barrowcliffe TW. The relative antithrombotic effectiveness of heparin, a low molecular weight heparin and a pentasaccharide fragment in an animal model. Thromb Haemost 1989, 61:204-207.
117. Cadroy Y, Hansson SR, Harker LA. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates. Thromb Haemost 1993, 70:631-635.
118. Boneu B, Necciari J, Canou R, Sie P, Gabaig AM, Kieffer G, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR 90107A/ORG 31540) with high affinity for antithrombin II in man. Thromb Haemost 1995, 74:1468-1473.
119. Bernat A, Herbert JM. Protamine sulfate inhibits pentasaccharide (SR 80027)-induced bleeding without affecting its antithrombotic and anti-factor Xa activity in the rat. Haemostasia 1996, 26:195-202.
120. Beijering RJR, van Olden RW, Stiekema J, ten Cate JW. Pentasaccharide in hemodialysis: a dose-finding study. Proceedings of the XVIth Congress of the International Society of Thrombosis and Haemostasis; 6-12 June 1997; Florence, Italy. Thromb Haemost 1997, (suppl 1):844 [abstract PS-1176].
121. Beijering RJR, van Olden RW, Stiekema J, ten Cate JW. Pentasaccharide in hemodialysis: a dose-finding study. Proceedings of the XVIth Congress of the International Society of Thrombosis and Haemostasis; 6-12 June 1997; Florence, Italy. Thromb Haemost 1997, (suppl 1):844 [abstract PS-1176].